MarketVIEW Chronic Disease Vaccines  ·  2020 edition

Alzheimer's Disease
Vaccines Forecast

Alzheimer's disease, the commonest cause of dementia, remains incurable, but the treatment landscape around it has been transformed since this report was last published. Two anti-amyloid monoclonal antibodies, lecanemab (Leqembi) and donanemab (Kisunla), are now approved and generating real-world revenue, while a smaller, earlier-stage field of active vaccine candidates, led by AC Immune's ACI-24.060 and a cluster of tau-targeting programmes, is working to achieve with a patient's own immune system what those infused antibodies currently do from the outside. This is a comprehensive, wide-geography commercial assessment of the Alzheimer's disease vaccine opportunity, drawing on VacZine Analytics' long-standing, independent expertise in Chronic disease vaccine markets.

57M+ Living With Dementia Worldwide 2 Anti-Amyloid Antibodies Now Approved AC Immune's ACI-24.060 in Phase 1b/2 Wide-Geography Forecast to 2035
Product catalogue
VAMV041
2020 edition

Format
Executive presentation + MS Excel model
Coverage
Major Western markets
Product types
Therapeutic & prophylactic
Risk groups
Adults, by AD severity stage
Forecast horizon
To 2035
Approach
Value ($m) & volume (mio doses) model
Base edition
2020
Availability
Syndicated / bespoke
57.4M
People living with dementia
worldwide (GBD 2019 baseline)
152.8M
Projected global dementia
cases by 2050
$2.8tn
Projected global cost of
dementia by 2030
2
Anti-amyloid antibodies now
approved: lecanemab, donanemab
Disease background

A fast-growing burden, and a treatment landscape transformed since this report's last edition

Alzheimer's disease has moved from a field with no disease-modifying option of any kind to one with two approved antibody therapies and an emerging active vaccine pipeline behind them. This review sets out the neuropathology and global burden before turning to that transformed competitive landscape.

Global burden data & 2025/26 pipeline update

Disease overview - Alzheimer's disease (AD)

Alzheimer's disease, first described by the German neurologist Alois Alzheimer in 1906, is a progressive neurodegenerative disorder and the most common cause of dementia, accounting for an estimated 60-70% of cases. Its neuropathology centres on two hallmark protein abnormalities: extracellular plaques formed from misfolded beta-amyloid peptide, and intracellular neurofibrillary tangles formed from hyperphosphorylated tau protein. The prevailing amyloid cascade hypothesis holds that abnormal amyloid processing triggers a downstream cascade of tau pathology, synaptic dysfunction, neuroinflammation and progressive neuronal loss, though the field increasingly treats amyloid and tau as two distinct, interacting therapeutic targets rather than a single linear pathway. Clinically, the disease progresses through a continuum from a preclinical, biomarker-positive stage, through mild cognitive impairment, to mild, moderate and severe dementia, a staged progression that shapes both treatment eligibility and this report's own severity-based demand segmentation.

The scale of the underlying dementia burden has grown substantially since this report's original 2020 edition, when the field still commonly cited the 2010 estimate of 35.6 million people living with dementia worldwide. The Global Burden of Disease Study 2019, the most recent peer-reviewed baseline with a published 2050 projection, put global dementia prevalence at 57.4 million people and forecast that figure will reach 152.8 million by 2050, a near-tripling driven overwhelmingly by population growth and ageing rather than any rise in underlying age-specific risk; other recent modelling, including WHO-cited estimates, puts the 2050 figure at closer to 139 million, with the range reflecting differing methodologies rather than genuine disagreement about direction of travel. Growth is projected to be sharpest in low- and middle-income regions, with north Africa and the Middle East and eastern sub-Saharan Africa both expected to see prevalence increases exceeding 350% by 2050, against much smaller increases of 53-74% in high-income Asia-Pacific and western Europe. The economic burden has kept pace: the global cost of dementia, spanning direct medical care, direct social care and informal caregiving, is projected to reach $2.8 trillion by 2030, while a separate value-of-statistical-life analysis published in The Lancet Global Health put the wider macroeconomic burden of Alzheimer's disease and related dementias at $14.5 trillion by 2050.

There remains no cure for the underlying neurodegeneration, and treatment for established dementia is still concentrated on managing symptoms with cholinesterase inhibitors and NMDA-receptor antagonists. What has genuinely changed since 2020 is the arrival, for the first time, of therapies that directly target and measurably clear the amyloid pathology itself, the anti-amyloid monoclonal antibodies covered in the next section, and behind them, an earlier-stage generation of active vaccine candidates trying to achieve a similar effect by prompting the patient's own immune system rather than infusing external antibody.

2026 57.4M living with dementia worldwide  |  152.8M projected by 2050  |  Lecanemab & donanemab both approved and prescribed  |  AC Immune's active vaccine ACI-24.060 in Phase 1b/2
Product & competitor landscape

Approved passive antibodies now in the clinic, active vaccines still earlier-stage behind them

This report distinguishes plainly between passive immunotherapies (monoclonal antibodies manufactured externally and infused) and active immunotherapies (true vaccines that prompt a patient's own immune system to generate antibodies). The passive antibody field is now approved and commercially established; the active vaccine field, the closer analogue to this report's own product category, remains genuinely earlier-stage.

  • Eisai / BiogenApproved 2023, passive antibody
    Lecanemab (Leqembi) Anti-amyloid monoclonal antibody, not a vaccine
    The first anti-amyloid antibody to receive full FDA approval, in July 2023, lecanemab clears aggregated amyloid protofibrils and plaque and has demonstrated a slowing of clinical decline of around 27% versus placebo in early symptomatic disease. Global revenue is still modest but growing quickly (sales up around 74% year-on-year into 2026), and in August 2025 the FDA approved a once-weekly subcutaneous maintenance formulation, following an 18-month intravenous induction period, intended to ease the treatment and monitoring burden for both patients and infusion capacity.
  • Eli LillyApproved 2024, passive antibody
    Donanemab (Kisunla) Anti-amyloid monoclonal antibody, not a vaccine
    Approved by the FDA in July 2024, donanemab targets a pyroglutamate form of amyloid found specifically in established plaque and is dosed on a limited-duration, stop-when-clear basis once plaque has been cleared on imaging, a distinct commercial and monitoring model from lecanemab's continuous dosing. Combined lecanemab and donanemab global revenue reached roughly $900 million in 2025 and is projected to exceed $2 billion by 2028 and reach $3-4 billion by 2030, positioning the anti-amyloid antibody class as a genuine, if still nascent, commercial category.
  • ARIA safety monitoringOngoing burden across the class
    Amyloid-related imaging abnormalities (ARIA)
    Both approved antibodies carry a boxed warning for ARIA, brain swelling or microhaemorrhage detected on MRI, affecting an estimated 15-25% of treated patients, with the highest risk concentrated among APOE4 carriers. Mandatory serial MRI monitoring, concentrated in the first six months of treatment when most events occur, remains the single largest real-world barrier to broader uptake, and is a factor this report's demand model explicitly weighs against the growing prescriber and patient acceptance of the class.
  • AC ImmunePhase 1b/2, active vaccine (ABATE trial)
    ACI-24.060 Active immunotherapy, anti-amyloid-beta vaccine
    A liposomal active vaccine using an Abeta 1-15 immunogen, ACI-24.060 is designed to raise antibodies with a binding profile against pathological amyloid species, including pyroglutamate and oligomeric forms, that mirrors clinically validated monoclonal antibodies such as lecanemab, but generated by the patient's own immune system. The ongoing Phase 1b/2 ABATE trial, in patients with prodromal-to-mild Alzheimer's disease and in adults with Down syndrome (who face markedly elevated Alzheimer's risk), has reported positive interim safety and clear anti-Abeta antibody responses across its dose cohorts, and the programme holds FDA Fast Track designation, with IND clearance enabling expansion of the trial into the United States.
  • AC Immune / JanssenPhase 1b/2a, active vaccine, tau-targeting
    ACI-35.030 & JACI-35.054 Active immunotherapy, phospho-tau vaccine
    A liposome-displayed phosphorylated-tau vaccine, ACI-35.030 (and its optimised variant JACI-35.054) is designed to raise antibodies selectively against pathological phospho-tau species rather than normal tau. Phase 1b/2a safety and immunogenicity results published in 2025 showed early, tau-specific antibody responses that were sustained over time, and data presented at the AD/PD 2025 conference showed the resulting antibodies inhibited uptake of tau aggregates into cells in laboratory models, a mechanistically encouraging, though still early-stage, signal that AC Immune has said will support continued development of the candidate.
  • Axon NeurosciencePhase 2, active vaccine (NIH Tau Platform trial)
    AADvac1 Active immunotherapy, tau-targeting vaccine
    A tau-peptide conjugate vaccine, AADvac1 previously showed a favourable safety profile and biomarker signals, including a positive post-hoc association with plasma p-tau217, in earlier Phase 2 testing. It was selected as the first tau-targeting therapy in a USD 151 million NIH-funded Alzheimer's Disease Tau Platform trial, which began dosing patients with late preclinical or early prodromal Alzheimer's disease in November 2025; results were not yet reported as of early 2026.
Field maturity, honestly stated
0 vaccines approved

No Alzheimer's vaccine, active or otherwise, is approved anywhere today. The passive monoclonal antibody field, lecanemab and donanemab, is now clinically and commercially established, generating real prescriptions and real revenue, but both carry a meaningful ARIA monitoring burden and neither halts the disease outright. The active vaccine field sits well behind that curve: AC Immune's ACI-24.060 and its tau-targeting programmes, together with Axon Neuroscience's AADvac1, are producing genuine, encouraging immunogenicity and safety signals, but all remain in Phase 1 or Phase 2 testing with no efficacy readout yet reported. VacZine Analytics' consistent view, reflected throughout the model, is that vaccine-specific clinical progress in Alzheimer's disease remains genuinely earlier-stage than the antibody space, not a substitute for it in the near term, a distinction this report treats as central to any credible commercial forecast.

Scope of analysis

Six analytical layers - one commercial picture

This is a genuinely comprehensive report with a wide geographic focus, spanning amyloid/tau neuropathology and global burden, the full immunotherapy competitive landscape, and value/volume demand forecasting by product type and risk group across major Western markets to 2035.

Wide-geography demand forecast

Value ($m) and volume (mio doses) demand modelling to 2035 across major Western markets.

Competitor & pipeline review

Full review of approved lecanemab and donanemab and the active vaccine field, including ACI-24.060, ACI-35.030 and AADvac1.

Product type & severity segmentation

Therapeutic and prophylactic product types, modelled separately for adult risk groups by Alzheimer's disease severity stage.

Pricing & penetration assumptions

Timeframe, pricing and penetration estimates informed by real-world lecanemab and donanemab uptake and ARIA monitoring constraints.

Disease burden & epidemiology

Updated global burden review incorporating current dementia prevalence data and 2050 projections.

Early decision-making support

Designed as an ideal tool to aid early-stage decision making in Alzheimer's vaccine positioning, investment and market entry planning.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the segment, geography and product-type framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.

SegmentGeographyProduct typeSeverity stageRevenue scenario
Adults, mild ADMajor Western marketsTherapeuticMild dementiaModelled
Adults, moderate ADMajor Western marketsTherapeuticModerate dementiaModelled
At-risk adults, prophylactic scenarioMajor Western marketsProphylacticPre-symptomaticModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAll geographiesAll product typesAll severity stages$███m
Full model in the licensed workbook
Major Western markets · to 2035 · therapeutic & prophylactic · by AD severity stage
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations evaluating the Alzheimer's disease vaccine opportunity against a backdrop of newly approved antibody therapies and an earlier-stage active vaccine pipeline.

  • Executive presentation - amyloid/tau neuropathology, global burden and full competitive review across active vaccine and passive antibody modalities
  • MS-Excel value/volume forecast model - value ($m) and volume (mio doses) demand outputs to 2035, by product type and risk group
  • Major Western market coverage - modelled individually and in aggregate
  • Product-type segmentation - therapeutic and prophylactic use cases, modelled separately
  • Risk-group segmentation - adult risk groups modelled by Alzheimer's disease severity stage
  • Competitor intelligence - approved lecanemab and donanemab, and the active vaccine field led by AC Immune and Axon Neuroscience
  • Updated epidemiology module - current global dementia burden data and projections to 2050
  • Early decision-making support - target product profile and market entry guidance for a still-forming vaccine category
Target audience

Built for organisations evaluating the Alzheimer's disease vaccine opportunity

Most valuable to teams assessing the Alzheimer's immunotherapy market against their own pipeline, BD ambitions or investment thesis, at a moment when approved antibodies have proven the amyloid target and active vaccine candidates are working to translate that validation into a genuinely preventive product.

Vaccine & biologics developers

Positioning and commercial feasibility assessment for amyloid- or tau-targeting candidates, active or passive, at any stage.

Corporate strategy & BD

Validate the size and structure of a vaccine opportunity sitting alongside a newly commercial antibody category, ahead of the field's next major readouts.

Investors & analysts

Independent, non-conflicted assessment of pipeline risk across AC Immune, Axon Neuroscience and the approved-antibody incumbents.

Public health & neurology programmes

Demand modelling to support future Alzheimer's immunisation and immunotherapy access planning, including ARIA monitoring capacity implications.

Researchers & academia

Comprehensive epidemiology and R&D landscape for grant and translational amyloid/tau vaccine research planning.

Market access & policy

Pricing benchmarks and access-pathway assumptions informed by real-world lecanemab and donanemab reimbursement experience.

About this analysis · VAMV041

VacZine Analytics has drawn on its long-standing expertise in Chronic diseases since our earliest editions, positioning us to revisit the Alzheimer's disease vaccine opportunity now that the field around it has been reshaped by the approval of lecanemab and donanemab, and by the first genuine clinical progress from active vaccine candidates such as AC Immune's ACI-24.060. This is a very comprehensive report with a wide geographic focus, and it has been well received by clients in the field for the depth of its epidemiology, pipeline and forecasting detail. Few groups have followed this historically slow-moving, high-risk market as closely, and that recognised, independent expertise underpins everything in the analysis.

This report was last published in 2020; any refresh would incorporate current global dementia burden data and 2050 projections, the transformed competitive landscape following the approvals of lecanemab (Leqembi) and donanemab (Kisunla), and the earlier-stage active vaccine field, including AC Immune's ACI-24.060, ACI-35.030 and Axon Neuroscience's AADvac1. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV041 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Alzheimer's disease vaccine analysis, a briefing call is included on request.